11 July 2025
Image Credits: MedTech Spectrum
This year, at the Society of Nuclear Medicine and Molecular Imaging annual meeting, GE Healthcare highlighted an innovative technological solution by presenting an advanced portfolio of theranostics-enabling solutions. This solution is introduced to support operational and clinical excellence. With the debut of GE Healthcare’s MIM software, the LesionID showcased its AI-powered innovation, automated zero-click pre-processing. This innovation will help therapy response monitoring and physicians in decision-making. The portfolio includes cyclotrons, radiopharmaceuticals, chemistry systems, and software that optimizes workflow.
Over 10 million deaths are registered each year due to cancer, which highlights the need for precision care. Theranostics is one of the new hopes for patients. The integration of radiopharmaceuticals and advanced diagnostic imaging with specific therapies, theranostics, provides a patient-centric and personalized approach. The approach will contribute to treatment accuracy, disease detection, and elevate the quality of life.
The practice of theranostics centers on molecular imaging, like single photon emission computed tomography (SPECT)and positron emission tomography (PET). This enables appropriate detail to patient-specific insights for monitoring and guiding treatment. Access to the insights of full body tumor burden calls out the total amount of cancer in the body. This insight has an analysis of the required time-consuming manual that evokes operational and clinical challenges.
In response to these challenges, GE Healthcare’s MIM software LesionID ID Pro helps access full-body tumor burden calculation by eliminating extra time in manually segmenting lesions. It also discards normal physiologic uptake and the registration of several patient images for comparison purposes. To convert manual pre-processing into a zero-click approach, the LesionID Pro with its enhanced algorithm helps physicians calculate tumor volume to finalize and review the reports.
The introduction of tools by known theranostics practitioners features a goal to develop a full-body tumor burden analysis, short time-to-report, and practical clinical reality.
MD, Phd, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine, said, “The future of theranostics and oncology is precision care. The combined AI-powered software and advanced imaging are leveraging the approach to theranostics in clinical practice.” Further, “The tools such as Starguide, MIM software, and GE Healthcare’s Omni legend have the potential to identify diseases with clarity, make the fastest decisions, and calculate tumor burden efficiently. These are the advancements, enhancing therapy monitoring and diagnostic accuracy. Additionally, it's also welcoming dosimetry that will support the patient's outcome. The precision care is an action fueling a real difference in patients' lives.”
11 July 2025
11 July 2025
11 July 2025
11 July 2025